CNTX-4975 appears to have failed its P3 clinical trials, like most of PAR's other so called competitors. Reality is there are no other major competitors yet, but Novartis is probably the biggest threat. Who knows, maybe Novartis may look to acquire PAR in the future if their candidate also fails trials.
https://endpts.com/exclusive-centrexions-knee-pain-drug-fails-two-phiii-studies-but-ex-pfizer-ceo-kindlers-biotech-might-still-ask-for-fda-nod/
Competition???, page-47
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |